WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 407833

CAS#: 2225902-88-3

Description: CMP3a is a NEK2 kinase inhibitor. CMP3a efficiently attenuated GBM growth in a mouse model and exhibited a synergistic effect with radiotherapy. Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2.

Price and Availability

Size Price Shipping out time Quantity
5mg USD 350 Same day
10mg USD 550 Same day
25mg USD 1050 Same day
50mg USD 1850 Same day
100mg USD 2950 Same day
Inquire bulk and customized quantity

Pricing updated 2021-01-25. Prices are subject to change without notice.

CMP3a, purity > 98%, is in stock. The same day shipping out after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 407833
Name: CMP3a
CAS#: 2225902-88-3
Chemical Formula: C28H27F3N6O2S
Exact Mass: 568.1868
Molecular Weight: 568.6192
Elemental Analysis: C, 59.14; H, 4.79; F, 10.02; N, 14.78; O, 5.63; S, 5.64

Synonym: CMP3a; CMP-3a; CMP 3a.

IUPAC/Chemical Name: (R)-5-{7-[1-(2-Dimethylamino-ethyl)-1H-pyrazol-4-yl]-imidazo[1,2-a]pyridin-3-yl}-3-[1-(2-trifluoromethyl-phenyl)-ethoxy]-thiophene-2-carboxamide


InChi Code: InChI=1S/C28H27F3N6O2S/c1-17(20-6-4-5-7-21(20)28(29,30)31)39-23-13-24(40-26(23)27(32)38)22-15-33-25-12-18(8-9-37(22)25)19-14-34-36(16-19)11-10-35(2)3/h4-9,12-17H,10-11H2,1-3H3,(H2,32,38)/t17-/m1/s1

SMILES Code: O=C(C1=C(O[C@@H](C2=CC=CC=C2C(F)(F)F)C)C=C(C3=CN=C4C=C(C5=CN(CCN(C)C)N=C5)C=CN43)S1)N

Technical Data

Yellow solid powder

>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:

Safety Data Sheet (SDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:

Additional Information

NEK2 was among the most differentially expressed kinase-encoding genes in GSC-containing cultures (glioma spheres), and it was required for in vitro clonogenicity, in vivo tumor propagation, and radioresistance. Mechanistically, the formation of a protein complex comprising NEK2 and EZH2 in glioma spheres phosphorylated and then protected EZH2 from ubiquitination-dependent protein degradation in a NEK2 kinase activity-dependent manner. Clinically, NEK2 expression in patients with glioma was closely associated with EZH2 expression and correlated with a poor prognosis. NEK2 expression was also substantially elevated in recurrent tumors after therapeutic failure compared with primary untreated tumors in matched GBM patients.


1: Wang J, Cheng P, Pavlyukov MS, Yu H, Zhang Z, Kim SH, Minata M, Mohyeldin A,
Xie W, Chen D, Goidts V, Frett B, Hu W, Li H, Shin YJ, Lee Y, Nam DH, Kornblum
HI, Wang M, Nakano I. Targeting NEK2 attenuates glioblastoma growth and
radioresistance by destabilizing histone methyltransferase EZH2. J Clin Invest.
2017 Aug 1;127(8):3075-3089. doi: 10.1172/JCI89092. Epub 2017 Jul 24. PubMed
PMID: 28737508; PubMed Central PMCID: PMC5531394.